Clinical Study
Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study
Table 4
Number and rates of secondary endpoints, tolerability and drop out occurrences during the trial.
| ā | ASA n=36 | controls n=47 |
| ā | n (%) | n (%) | Primary endpoint | 2 (5.6) | 9 (19.1) | Other cardiovascular events | 2 (5.6) | 1 (2.1) | Adverse events | 2 (5.6) | 2 (4.2) | Switch ASA | - | 2 (4.2) | Lost to follow-up | 9 (25.0) | 9 (19.1) | Mortality | - | 1 (2.1) | Low compliance | 2 (5.6) | - | Withdraws consent | 4 (11.1) | - |
| Completed follow-up | 15 (41.7) | 23 (48.9) |
|
|